title: [Curative efficacy analysis of allo-HSCT using conditioning regimen of FLAG combined with modified BUCY for refractory and relapsed patients with hematologic malignancies].
abstract: This study was aimed to investigate the curative efficacy of allogenetic hemopoietic stem cell transplantation (allo-HSCT) using FLAG and modified BUCY conditioning regimen for patients with refractory and relapse or high risk hematologic malignancies. The therapeutic effect of allo-HSCT with FLAG and modified BUCY conditioning regimen on 10 patients with hematologic malignancies was analyzed. 10 patients included 2 cases of relapse (1 early relapse, 1 progression) and 7 cases of refractory (2 CR(2), 1 CR(3) and 2 PR and 1 NR) and 1 CR(1) with high risk. Among 10 cases 8 cases was diagnosed as AML, 1 case as pro-T lymphoblast lymphoma/leukemia and 1 case as spleen marginal zone lymphoma. The results showed that implantation of all the patients was successful. The relapse-free median survival time of 8 cases was 164 days (57 - 442 days) and survived up to now, 2 cases died (1 case died of pulmonary infection, 1 case died of fungus pulmonitis). In conclusion, the curative efficacy of allo-HSCT using FLAG and modified BUCY conditioning regimen for patients with refractory and relapsed hematologic malignancies is satisfactory.
authors.affiliation: Department of Hematology, Clinical Division 304, Chinese PLA General Hospital, Beijing 100048, China.
authors.forename: Zhi-Hong
authors.initials: ZH
authors.lastname: Wang
authors.forename: Xiao-Xiong
authors.initials: XX
authors.lastname: Wu
authors.forename: Zhou-Yang
authors.initials: ZY
authors.lastname: Liu
authors.forename: Jian
authors.initials: J
authors.lastname: Ma
authors.forename: Yong-Bin
authors.initials: YB
authors.lastname: Cao
authors.forename: Li-Xin
authors.initials: LX
authors.lastname: Xu
authors.forename: Ya-Mei
authors.initials: YM
authors.lastname: Wu
authors.forename: Bei
authors.initials: B
authors.lastname: Liu
authors.forename: Bei
authors.initials: B
authors.lastname: Yan
authors.forename: Wan-Ming
authors.initials: WM
authors.lastname: DA
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D005260:Female; D019337:Hematologic Neoplasms / Q000601:surgery / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D008297:Male; D008875:Middle Aged; D019172:Transplantation Conditioning / Q000379:methods*; D055815:Young Adult